Cytotoxic effects of human calprotectin on gastric cancer cell line is attenuated by etoposide

Gastroenterology and Hepatology from Bed to Bench

Volumn 5, Issue 3, 2012, Pages 132-138

  Zali, Hakimeh ^a   Zamanian Azodi, Mona ^a   Shokrgozar, Mohamad Ali ^b   Rezaei Tavirani, Mostafa ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AGS cell line; Calprotectin; Etoposide; Inhibition proliferation; MTT assay

Indexed keywords

CALGRANULIN; CYTOTOXIC AGENT; ETOPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SCREENING; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; STOMACH CANCER; TUMOR CELL LINE;

EID: 84866519666     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pakarinen M, Koivusalo A, Natunen J, Ashorn M, Karikoski R, Aitola P, et al. P027 fecal calprotectin mirrors inflammation of the pulled through ileum and bowel function after restorative proctocolectymy for rediatric onset ulceractive colitis. J Crohn's Colitis Supplements 2009; 3:8.
2. Rezaei Tavirani M, Zali H, Nasiri S, Shokrgozar MA. Human Calprotectin, a Potent Anticancer with Minimal Side Effectjranian journal of cancer prevention, 2009; 2:1 83-88.
3. Zali H, Rezaei-Tavirani M, Kariminia A, Yousefi R, Shokrgozar MA. Evaluation of Growth Inhibitory and Apoptosis Inducing Activity of Human Calprotectin on the Human Gastric Cell Line (AGS). Iranian Biomed J 2008; 12: 7-14.
4. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), An inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. J Biol Pharm Bull 2003; 26: 753-60. (Pubitemid 39655290)
5. Nakatani Y, Yamazaki M, Chazin WJ, Yui S. Regulation of S100A8/A9 (calprotectin) binding to tumor cells by zinc ion and its implication for apoptosis-inducing activity. Mediators Inflamm 2005;24: 280-92. (Pubitemid 41577418)
6. Wong EV, Schaefer AW, Landreth G, Lemmon V. Casein kinase II phosphorylates the neural cell adhesion molecule LI. J Neurochem 1996; 66: 779-86. (Pubitemid 26036710)
7. Chen Y , Su YH, Wang CH, Wu JM, Chen JC, Tseng SH. Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor). Anticancer Res 2005; 25:4203-8. (Pubitemid 41665205)
8. McClendon AK, Osheroff N. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.Biochem 2006; 745: 3040-50. (Pubitemid 43334552)
9. Barker CR, McNamara AV, Rackstraw SA, Nelson ED, White MR, Watson AJ, et al. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids Res 2006; 34:1148-57.
10. Stahl S, Kasimir-Bauer M, Harstrick A. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. Anticancer Drugs 1997; 8: 671-76. (Pubitemid 27404724)
11. Sortibran AN, Tellez MG, Rodriguez-Arnaiz R. Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster. Mutat Res 2006; 604:83-90.
12. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J Cancer 1998; 34: 1514-21. (Pubitemid 28446331)
13. Duca M, Guianvarc'h D, Oussedik K, Halby L, Garbesi A, Dauzonne D, et al. Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by etoposide derivatives conjugated to triplex-forming oligonucleotides. Nucleic Acids Res 2006; 34: 1900-11.
14. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 2005; 4: 219-34. (Pubitemid 40867335)
15. Zali H, Marashi SA, Rezaei-Tavirani M, Toossi P, Rahmati-Roodsari M, Shokrgozar MA. On the mechanism of apoptosis-inducing activity of human calprotectin: Zinc sequestration, induction of a signaling pathway, or something else? Med Hypotheses 2007; 68:1012-15.
16. Marashi SA, Rezaei-Tavirani M, Zali H, Shokrgozar MA. Mitochondrial DNA might be influenced in calprotectin-induced cell death. Exper and Clinic Sciences Inter J 2008; 7:163-68.
17. Muller G, Kerkhoff C, Hankowitz J, Pataki M, Kovacs E, Lackner KJ, et al. Effects of purinergic agents on human mononu-clear phagocytes are differentiation dependent. Implications for athero-genesis. Arterioscler Thromb 1993;13:1317-26. (Pubitemid 23271134)
18. van den Bos C, Rammes A, Vogl T, Boynton R, Zaia J, Sorg C, Roth I Copurification of P6, MRP8, and MRP 14 from human granulocytes and separation of individual proteins, Protein Expr. Purif 1998;13:313-18. (Pubitemid 28378824)
19. Yousefi R, Ardestan SK, Saboury A, Kariminia A, Zeinali M, Amani M. Investigation on the surface hydrophobicity and aggregation kinetics of human calprotectin in the presence of calcium. J Biochem Mol Biol 2005;38:407-13. (Pubitemid 43034351)
20. Moldeus T, Hogberg J, Orrhenius S, Fleischer S, Packer L. Trypan blue dye exclusion method, Meth. Enzyme 1978;52:60-71.
21. Francis D, Rapid RL. Colorometric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, J. Immunol.Meth 1986;89:271-77.
22. Booker HE, and Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 1973;14: 177-84.
23. Kunin CM. Influence of binding on the pharmacologic activity of antibiotics. Ann NY Acad Sci 1973;226: 214-24.
24. McDevitt DG, Frisk-Holmberg M, Hollifield JW, Shand DG. Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther 1976;20: 152-57.
25. Lima JJ, Boudoulas H, Blanford M. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics. J Pharmacol Exp Ther 1981;219:741-47. (Pubitemid 12248837)
26. Stewart CF, Arbuck SG, Pieper JA, Evans WE. Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 1989;45:49-55. (Pubitemid 19047146)
27. Stewart CF, Fleming RA, Evans WE. In vitro evaluation of etoposide (VP) plasma protein binding. Pharm Res 1989;6:197.
28. Stewart, CF, Arbuck SG, Fleming RA, Evans WE. Leukopenia and etoposide systemic exposure: clinical relevance of nonprotein bound etoposide. Proc Am Soc Clin Oncol 1989;71.